The pharmaceutical industry of the USA was shaken by important news. US Administration, Boston-based pharmaceutical giant Alexion Pharmaceuticals Inc. , fined a $ 21 million penalty for operations undertaken in 2 countries for the drug Soliris. According to the U.S. Securities and Exchange Commission (SEC), Alexion Pharmaceuticals Inc.’s book records were reviewed.
It was determined that there were some violations in the accounting records of the company between 2010 and 2015. In the studies conducted, it was stated that the Boston-based company’s Corruption Practices Act (FCPA) was violated and abused. In the examination officials in Turkey and Russia it was allegedly paid money to influence improperly.
Chose to deal
The Boston pharmaceutical company opted for an agreement with the SEC instead of rejecting or accepting claims. Thus, the company announced that it would pay the US Government $ 21 million. In the Select statement by the drug Soliris from Alexion Pharmaceuticals it was stated that Turkey begin to be sold in 2009.